BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8205523)

  • 1. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice.
    Hinz HR; Harris NJ; Natelson EA; Giovanella BC
    Cancer Res; 1994 Jun; 54(12):3096-100. PubMed ID: 8205523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
    Zamboni WC; Goel S; Iqbal T; Parise RA; Strychor S; Repinski TV; Egorin MJ; Mani S
    Cancer Chemother Pharmacol; 2006 May; 57(5):631-9. PubMed ID: 16205924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
    Jung LL; Ramanathan RK; Egorin MJ; Jin R; Belani CP; Potter DM; Strychor S; Trump DL; Walko C; Fakih M; Zamboni WC
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):487-96. PubMed ID: 15322760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
    Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
    Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.
    Zamboni WC; Strychor S; Joseph E; Parise RA; Egorin MJ; Eiseman JL
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):417-26. PubMed ID: 17957368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro.
    Pantazis P; Early JA; Mendoza JT; DeJesus AR; Giovanella BC
    Cancer Res; 1994 Feb; 54(3):771-6. PubMed ID: 8306340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
    Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
    Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.
    Frapolli R; Zucchetti M; Sessa C; Marsoni S; ViganĂ² L; Locatelli A; Rulli E; Compagnoni A; Bello E; Pisano C; Carminati P; D'Incalci M
    Eur J Cancer; 2010 Feb; 46(3):505-16. PubMed ID: 20007015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
    Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
    Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
    Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
    Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).
    Giovanella BC; Stehlin JS; Hinz HR; Kozielski AJ; Harris NJ; Vardeman DM
    Int J Oncol; 2002 Jan; 20(1):81-8. PubMed ID: 11743646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro.
    Pantazis P; Mendoza JT; Early JA; Kozielski AJ; Natelson EA; Giovanella BC
    Eur J Haematol; 1993 Feb; 50(2):81-9. PubMed ID: 8440362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro.
    Pantazis P; Early JA; Kozielski AJ; Mendoza JT; Hinz HR; Giovanella BC
    Cancer Res; 1993 Apr; 53(7):1577-82. PubMed ID: 8453626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
    Zuo Z; Tam YK; Diakur J; Wiebe LI
    J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats.
    Zhong DF; Li K; Xu JH; Du Y; Zhang YF
    Acta Pharmacol Sin; 2003 Mar; 24(3):256-62. PubMed ID: 12617776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
    Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.
    Tedesco KL; Berlin J; Rothenberg M; Choy H; Wyman K; Scott Pearson A; Daniel Beauchamp R; Merchant N; Lockhart AC; Shyr Y; Caillouette C; Chakravarthy B
    Radiother Oncol; 2005 Jul; 76(1):54-8. PubMed ID: 15921772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical determination and pharmacokinetics of robenacoxib in the dog.
    Jung M; Lees P; Seewald W; King JN
    J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
    Schluep T; Cheng J; Khin KT; Davis ME
    Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.